The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View lym content recommended for you

EHA2023 abstracts: What’s hot in lymphoma and CLL?

By Abhilasha Verma,Quintina Dawson

Jun 7, 2023

To help navigate the exciting content being presented at the EHA2023 Congress, the Lymphoma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in lymphoma and chronic lymphocytic leukemia.

Indolent and mantle cell NHL

S220	Real-world outcomes of brexucabtagene autoleucel (BREXU-CEL) for relapsed or refractory mantle cell lymphoma: a CIBMTR subgroup analysis by prior treatment
S221	Long-term results of the FIL MCL0208 trial comparing lenalidomide maintenance (LEN) vs observation (OBS) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL)
S222	Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status
S223	Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory follicular lymphoma
P1080	Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
P1078	Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal phase II study
P1107	ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma

Hodgkin lymphoma

S217	Post-transplant nivolumab plus unselected autologous lymphocytes in refractory Hodgkin lymphoma results in very high remission rate and excellent survival and it is associated with NK cell expansion
S218	Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized GHSG trials
S219	Predicting thrombotic risk in patients with H odgkin lymphoma: a multicentric study of ThroLy and Khorana risk scores

T-cell lymphoma

S225	Allogeneic stem cell transplantation for NK/T-CELL lymphoma in the era of asparaginase-based chemotherapy: a retrospective analysis of the EBMT lymphoma working party
S226	Efficacy of anti-PD1 therapy in relapsed or refractory extranodal NK/T cell lymphoma: a matched cohort analysis from the LYSA
S237	The genetic subtypes and the tumor microenvironment signatures are associated with distinct outcomes in peripheral T-cell lymphoma

Aggressive B-NHL

S227	Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-POLA-MINI-CHP and R-MINI-CHOP
S229	Prophylactic efficacy of intrathecal versus intravenous methotrexate for CNS relapse in high-risk diffuse large B cell lymphoma : a phase III randomized, controlled study
S230	CD22 CAR T cell therapy is safe and effective in patients with large B cell lymphoma who have relapsed after CD19 car t cell therapy.
S233	Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma in transplant-ineligible patients: final analysis of ALYCANTE, a phase 2 LYSA study
S234	Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma
P1127	Final analysis of Australasian leukaemia & lymphoma group NHL29: a phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL
P1129	Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study
P1154	Efficacy of subcutaneous epcoritamab vs axi-cel in R/R DLBCL CAR T-naive and CAR T-eligible patients: an indirect comparison

Chronic lymphocytic leukemia

S144	BTK and BCL-2 activity at baseline predicts MRD status for chronic lymphocytic leukemia patients treated with ibrutinib + venetoclax in the HOVON 141/VISION trial
S145	Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia : 6-year results of the randomized CLL14 study
S146	Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (CBTKI) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I/II BRUIN study
S200	Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): final results of the phase 3, double-blind, placebo-controlled CLL12 trial
S201	Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax -rituximab (VENR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

Advances in disease biology

S257

CAR T cells and their immune environment shape distinct immune profiles in response and toxicity in B cell lymphoma patients

EHA 2023 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2023

Subscribe to get the best content delivered to your inbox